FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to oncology and can be used in combined treatment of cancer. Versions of pharmaceutical preparation according to the invention include 7-tret-butoxyiminomethylcamptothecin and other chemical therapeutic agent. The inventions also relate to application of 7-tert-butoxyiminomethylcamptothecin for obtaining medication for application in combination with one or several chemical therapeutic agents.
EFFECT: application of the inventions allows to increase anti-tumour effect due to enhancement of cytotoxic effect with respect to tumour cells due to synergetic action of components.
9 cl, 18 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORS OF CELL CYCLE CHECKPOINT KINASE 1 FOR AMPLIFICATION OF DNA-DAMAGING AGENTS | 2010 |
|
RU2567044C2 |
| METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS | 2007 |
|
RU2492864C2 |
| PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY | 2013 |
|
RU2659936C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| COMBINATIONS INCLUDING EPOTHILONES, AND THEIR PHARMACEUTICAL APPLICATION | 2002 |
|
RU2375058C2 |
| QUINOLINE DERIVATIVES FOR USE IN TREATMENT OR PREVENTION OF CANCER | 2019 |
|
RU2811417C2 |
| METHOD OF TREATING CANCER (VERSIONS) | 2006 |
|
RU2447889C2 |
| PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
